NOTCH1 and head and neck squamous cell carcinoma: One patient with heavily pretreated R/M HNSCC with a LOF NOTCH1 mutation was enrolled in a phase-I study of bimiralisib and had a PR (85% reduction in target lesion) that was sustained for 36 weeks [89].